EMA Authorised: Uplizna (inebilizumab) — Amgen Europe B.V.

View source ↗

Summary

The European Medicines Agency has authorised Uplizna (inebilizumab) for the treatment of Neuromyelitis Optica in adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica

Drugs mentioned

• Uplizna (inebilizumab)

Snippet

Status: Authorised. Therapeutic area: Neuromyelitis Optica. MAH: Amgen Europe B.V.. Decision date: 10/02/2026